{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:31Z","timestamp":1740185011159,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Sarkopenie ist die Verminderung der Muskelkraft und -masse sowie Einschr\u00e4nkung der Funktion. Das Ziel der vorliegenden Studie war es zu untersuchen, ob die anhand der Psoasmuskulatur bestimmte pr\u00e4therapeutische Sarkopenie die therapievermittelte Toxizit\u00e4t bei Patienten mit malignem Melanom unter einer Immuncheckpoint-Inhibition beeinflusst.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patienten und Methoden<\/jats:title>\n                <jats:p>Die Vermessung der Psoasmuskulatur erfolgte pr\u00e4therapeutisch mithilfe der Computertomographie auf der H\u00f6he des 3.\u00a0Lendenwirbelk\u00f6rpers (LWK) bei 75\u00a0Patienten zwischen Januar 2011 und Dezember 2020. Die Sarkopenie wurde anhand des Psoasmuskelindex (PMI) definiert. Die immunvermittelte Toxizit\u00e4t wurde retrospektiv ermittelt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Bei 33\u00a0der 75\u00a0Patienten (44\u202f%) wurde eine behandlungsbedingte Toxizit\u00e4t unter Therapie mit Immuncheckpoint-Inhibitoren registriert. Davon erlitten 16\u00a0Patienten (36,2\u202f%) eine dosislimitierende schwere Toxizit\u00e4t (DLT). Eine pr\u00e4therapeutische Sarkopenie wurde bei 25\u00a0Patienten (33,3\u202f%) ermittelt. Die Vergleichsanalyse ergab, dass die Patienten mit einer DLT im Vergleich zu der Patientengruppe ohne DLT niedrigere PMI-Werte aufwiesen (4,65\u202f\u00b1\u20091,33 vs.\u00a05,79\u202f\u00b1\u20091,67\u202fcm<jats:sup>2<\/jats:sup>m<jats:sup>\u22122<\/jats:sup>, <jats:italic>p<\/jats:italic>\u202f=\u20090,015) (OR\u202f=\u20090,60, 95\u202f%-KI: 0,40\u20130,92, <jats:italic>p<\/jats:italic>\u202f=\u20090,02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Die anhand der Psoasmuskulatur gemessene pr\u00e4therapeutische Sarkopenie ist kein signifikanter Pr\u00e4diktor f\u00fcr DLT bei Patienten mit malignem Melanom unter einer Immuncheckpoint-Inhibition. Patienten mit einer DLT weisen jedoch im Vergleich zu der Patientengruppe ohne DLT niedrigere Werte f\u00fcr die Psoasmuskelparameter PMI und Gauge auf.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-024-05405-9","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T18:02:16Z","timestamp":1723658536000},"page":"798-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Die Bedeutung von Sarkopenie f\u00fcr die immunvermittelte Toxizit\u00e4t bei Patienten mit malignem Melanom unter einer Immuncheckpoint-Inhibition","Sarcopenia and immune-related toxicity in patients with malignant melanoma undergoing immune checkpoint inhibition"],"prefix":"10.1007","volume":"75","author":[{"given":"Christian","family":"Holtorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Mengoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"T\u00fcting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Borggrefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Surov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"5405_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft\u00a0AJ, Bahat\u00a0G, Bauer\u00a0J et\u00a0al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331","journal-title":"Age Ageing"},{"key":"5405_CR2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","volume":"37","author":"F Pamoukdjian","year":"2018","unstructured":"Pamoukdjian\u00a0F, Bouillet\u00a0T, L\u00e9vy\u00a0V, Soussan\u00a0M, Zelek\u00a0L, Paillaud\u00a0E (2018) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A\u00a0systematic review. Clin Nutr 37:1101\u20131113","journal-title":"Clin Nutr"},{"key":"5405_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000356760","volume":"60","author":"S Ali","year":"2014","unstructured":"Ali\u00a0S, Garcia\u00a0JM (2014) Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options\u2014A Mini-Review. Gerontology 60:294\u2013305","journal-title":"Gerontology"},{"key":"5405_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/jso.23862","volume":"111","author":"S Joglekar","year":"2015","unstructured":"Joglekar\u00a0S, Asghar\u00a0A, Mott\u00a0SL, Johnson\u00a0BE, Button\u00a0AM, Clark\u00a0E, Mezhir\u00a0JJ (2015) Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma: Sarcopenia in Pancreatectomy. J\u00a0Surg Oncol 111:771\u2013775","journal-title":"J Surg Oncol"},{"key":"5405_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jamcollsurg.2015.12.020","volume":"222","author":"S Buettner","year":"2016","unstructured":"Buettner\u00a0S, Wagner\u00a0D, Kim\u00a0Y, Margonis\u00a0GA, Makary\u00a0MA, Wilson\u00a0A, Sasaki\u00a0K, Amini\u00a0N, Gani\u00a0F, Pawlik\u00a0TM (2016) Inclusion of Sarcopenia Outperforms the Modified Frailty Index in Predicting 1\u2011Year Mortality among 1,326 Patients Undergoing Gastrointestinal Surgery for a\u00a0Malignant Indication. J\u00a0Am Coll Surg 222:397\u2013407","journal-title":"J Am Coll Surg"},{"key":"5405_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10637-017-0464-x","volume":"35","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger\u00a0V, Goldwasser\u00a0F, Kramkimel\u00a0N et\u00a0al (2017) Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs 35:436\u2013441","journal-title":"Invest New Drugs"},{"key":"5405_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly\u00a0LE, Power\u00a0DG, O\u2019Reilly \u00c1, Donnellan\u00a0P, Cushen\u00a0SJ, O\u2019Sullivan\u00a0K, Twomey\u00a0M, Woodlock\u00a0DP, Redmond\u00a0HP, Ryan\u00a0AM (2017) The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer 116:310\u2013317","journal-title":"Br J Cancer"},{"key":"5405_CR8","doi-asserted-by":"publisher","first-page":"O20","DOI":"10.1111\/codi.12805","volume":"17","author":"KI Jones","year":"2015","unstructured":"Jones\u00a0KI, Doleman\u00a0B, Scott\u00a0S, Lund\u00a0JN, Williams\u00a0JP (2015) Simple psoas cross-sectional area measurement is a\u00a0quick and easy method to assess sarcopenia and predicts major surgical complications. Colorectal Dis 17:O20\u2013O26","journal-title":"Colorectal Dis"},{"key":"5405_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00384-017-2773-0","volume":"32","author":"M Hanaoka","year":"2017","unstructured":"Hanaoka\u00a0M, Yasuno\u00a0M, Ishiguro\u00a0M, Yamauchi\u00a0S, Kikuchi\u00a0A, Tokura\u00a0M, Ishikawa\u00a0T, Nakatani\u00a0E, Uetake\u00a0H (2017) Morphologic change of the psoas muscle as a\u00a0surrogate marker of sarcopenia and predictor of complications after colorectal cancer surgery. Int J Colorectal Dis 32:847\u2013856","journal-title":"Int J Colorectal Dis"},{"key":"5405_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00384-020-03570-6","volume":"35","author":"G Simpson","year":"2020","unstructured":"Simpson\u00a0G, Manu\u00a0N, Magee\u00a0C, Wilson\u00a0J, Moug\u00a0S, Vimalachandran\u00a0D (2020) Measuring sarcopenia on pre-operative CT in older adults undergoing emergency laparotomy: a\u00a0comparison of three different calculations. Int J Colorectal Dis 35:1095\u20131102","journal-title":"Int J Colorectal Dis"},{"key":"5405_CR11","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"U.S. Department of health and human services","year":"2017","unstructured":"U.S. Department of health and human services (2017) Common Terminology Criteria for Adverse Events (CTCAE)"},{"key":"5405_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/tbj.12952","volume":"24","author":"MS Weinberg","year":"2018","unstructured":"Weinberg\u00a0MS, Shachar\u00a0SS, Muss\u00a0HB, Deal\u00a0AM, Popuri\u00a0K, Yu\u00a0H, Nyrop\u00a0KA, Alston\u00a0SM, Williams\u00a0GR (2018) Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a\u00a0curable breast cancer population. Breast\u00a0J 24:278\u2013284","journal-title":"Breast J"},{"key":"5405_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10151-020-02262-1","volume":"24","author":"SJ Moug","year":"2020","unstructured":"Moug\u00a0SJ, Barry\u00a0SJE, Maguire\u00a0S, Johns\u00a0N, Dolan\u00a0D, Steele\u00a0RJC, Buchan\u00a0C, Mackay\u00a0G, Anderson\u00a0AS, Mutrie\u00a0N (2020) Does prehabilitation modify muscle mass in patients with rectal cancer undergoing neoadjuvant therapy? A\u00a0subanalysis from the REx randomised controlled trial. Tech Coloproctology 24:959\u2013964","journal-title":"Tech Coloproctology"},{"key":"5405_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado\u00a0CM, Lieffers\u00a0JR, McCargar\u00a0LJ, Reiman\u00a0T, Sawyer\u00a0MB, Martin\u00a0L, Baracos\u00a0VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a\u00a0population-based study. Lancet Oncol 9:629\u2013635","journal-title":"Lancet Oncol"},{"key":"5405_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000525928","volume":"100","author":"A Surov","year":"2022","unstructured":"Surov\u00a0A, Meyer\u00a0H\u2011J, Wienke\u00a0A (2022) Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A\u00a0Meta-Analysis. Oncology 100:498\u2013504","journal-title":"Oncology"},{"key":"5405_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1210\/endrev\/bnaa016","volume":"41","author":"MCK Severinsen","year":"2020","unstructured":"Severinsen\u00a0MCK, Pedersen\u00a0BK (2020) Muscle\u2013Organ Crosstalk: The Emerging Roles of Myokines. Endocr Rev 41:594\u2013609","journal-title":"Endocr Rev"},{"key":"5405_CR17","first-page":"171","volume-title":"Sarcopenia Mol. Mech. Treat. Strateg","author":"W Aoi","year":"2021","unstructured":"Aoi\u00a0W (2021) Myokines: A\u00a0potential key factor in development, treatment, and biomarker of sarcopenia. In: Sarcopenia Mol. Mech. Treat. Strateg. Elsevier, S\u00a0171\u2013185"},{"key":"5405_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41577-019-0177-9","volume":"19","author":"NA Duggal","year":"2019","unstructured":"Duggal\u00a0NA, Niemiro\u00a0G, Harridge\u00a0SDR, Simpson\u00a0RJ, Lord\u00a0JM (2019) Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol 19:563\u2013572","journal-title":"Nat Rev Immunol"},{"key":"5405_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon\u00a0KC, Lugli\u00a0E, Welles\u00a0HC et\u00a0al (2015) Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer. J\u00a0Clin Oncol 33:74\u201382","journal-title":"J Clin Oncol"},{"key":"5405_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","volume":"15","author":"A Mar\u00e7ais","year":"2014","unstructured":"Mar\u00e7ais\u00a0A, Cherfils-Vicini\u00a0J, Viant\u00a0C et\u00a0al (2014) The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 15:749\u2013757","journal-title":"Nat Immunol"},{"key":"5405_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/gutjnl-2011-300776","volume":"62","author":"W Aoi","year":"2013","unstructured":"Aoi\u00a0W, Naito\u00a0Y, Takagi\u00a0T et\u00a0al (2013) A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut 62:882\u2013889","journal-title":"Gut"},{"key":"5405_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cmet.2017.09.015","volume":"27","author":"P Hojman","year":"2018","unstructured":"Hojman\u00a0P, Gehl\u00a0J, Christensen\u00a0JF, Pedersen\u00a0BK (2018) Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. Cell Metab 27:10\u201321","journal-title":"Cell Metab"},{"key":"5405_CR23","doi-asserted-by":"publisher","first-page":"E504","DOI":"10.1152\/ajpendo.00520.2010","volume":"301","author":"P Hojman","year":"2011","unstructured":"Hojman\u00a0P, Dethlefsen\u00a0C, Brandt\u00a0C, Hansen\u00a0J, Pedersen\u00a0L, Pedersen\u00a0BK (2011) Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol-endocrinol Metab 301:E504\u2013E510","journal-title":"Am J Physiol-endocrinol Metab"},{"key":"5405_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman\u00a0JT, Meibohm\u00a0B (2017) Pharmacokinetics of Monoclonal Antibodies: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacomet Syst Pharmacol 6:576\u2013588","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"5405_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/jcsm.12538","volume":"11","author":"MP Chu","year":"2020","unstructured":"Chu\u00a0MP, Li\u00a0Y, Ghosh\u00a0S, Sass\u00a0S, Smylie\u00a0M, Walker\u00a0J, Sawyer\u00a0MB (2020) Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J\u00a0cachexia sarcopenia muscle 11:748\u2013755","journal-title":"J cachexia sarcopenia muscle"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05405-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05405-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:04:17Z","timestamp":1727791457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05405-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5405"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05405-9","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"18 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Alter hat in den letzten 5\u00a0Jahren Zuwendungen f\u00fcr Vortr\u00e4ge oder Beratung von folgenden Unternehmen erhalten: Bristol-Myers Squibb, Roche Pharma, Merck Sharp Dohme, Novartis, Merck-Serono, Amgen, Almirall Hermal, Pierre Fabre, Sun Pharma, Sanofi\/Regeneron, UCB, Janssen-Cilag, Pfizer, AbbVie und Incyte. M.\u00a0Mengoni hat in den letzten 5\u00a0Jahren Zuwendungen f\u00fcr Vortr\u00e4ge, Beratung und Kongressunterst\u00fctzungen von folgenden Unternehmen erhalten: Merck Sharp Dohme, Bristol-Myers Squibb, Novartis, Stemline Therapeutics, Kyowa Kirin, Pierre Fabre, Sun Pharma, LEO Pharma. C.\u00a0Holtorf, A.\u00a0Surov, J.\u00a0Borggrefe, T.\u00a0T\u00fcting und A.\u00a0Wienke geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor. Die wissenschaftliche Arbeit wurde von der Ethikkommission der Otto-von-Guericke-Universit\u00e4t in Magdeburg bewilligt und unter Ber\u00fccksichtigung der regulatorischen Ma\u00dfgaben der guten klinischen Praxis (GCP) durchgef\u00fchrt. Ethikvotum: 145\/21.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}